Rikke

Pharvaris reports fourth quarter and full year 2023 financial results and provides business update Pharvaris reported financial results for the fourth quarter and year ended 31 December 2023, and provided a business update. Berndt Modig, Chief Executive Officer of Pharvaris, said: “2024 is off to a strong start, supported by the incredible momentum we [...]

Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference Pharvaris announced the acceptance of two abstracts for presentation at the Consortium of Independent Immunology Clinics (CIIC) Spring 2024 Conference, to be held from 12-13 April 2024, in Arlington, Texas, United States of America. Presentation details: Title: Early-Onset Response to the Oral [...]

21 March 2024 KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas KalVista Pharmaceuticals announced that it presented multiple analyses of the relationship between the time to attack treatment and the effects delays in treatment have on clinical outcomes of people living with [...]

Pharvaris announces Phase 3 clinical study design for recently initiated RAPIDe-3 study, and presents quality-of-life improvement and caregiver behavior data at two recent HAE congresses Pharvaris presented at two recent congresses: the 3rd National Congress of the Italian Network for Hereditary and Acquired Angioedema (ITACA) and the 2024 HAE International (HAEi) Regional Conference Americas. [...]

Pharming Group reports fourth quarter and full year 2023 financial results Pharming Group presents its preliminary (unaudited) financial report for the three months and full year ended 31 December 2023. Sijmen de Vries, Chief Executive Officer, commented: “We are pleased to have delivered an excellent year in which we transformed Pharming into a multiproduct, [...]

KalVista Pharmaceuticals awarded UK Promising Innovative Medicine (PIM) designation for sebetralstat KalVista Pharmaceuticals today announced the UK Medicines and Healthcare products Regulatory Agency (MHRA) has awarded the Promising Innovative Medicine (PIM) designation for sebetralstat, an investigational novel, oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema (HAE). The PIM is the first [...]

KalVista Pharmaceuticals reports third fiscal quarter results and provides operational update KalVista Pharmaceuticals today provided an operational update and released financial results for the third fiscal quarter ended 31 January 2024. Ben Palleiko, Chief Executive Officer of KalVista, said: “This has been an exciting and busy period for KalVista, as we achieved key milestones [...]

KalVista Pharmaceuticals to present HAE attack journey data at 2024 HAEi Regional Conference Americas KalVista Pharmaceuticals today announced the acceptance of multiple abstracts at the 2024 HAEi Regional Conference meeting taking place in Panama City, Panama from 15-17 March 2024. KalVista is a Silver-level sponsor of the meeting. The presentations are: Relationship Between Time [...]

Astria Therapeutics reports fourth quarter and full year 2023 financial results and provides a corporate update Astra Therapeutics today announced today reported financial results for the fourth quarter and full year ended 31 December 2023, and provided a corporate update. Jill C Milne, Chief Executive Officer at Astria Therapeutics, said: “We have strong conviction [...]

BioCryst reports fourth quarter and full year 2023 financial results and upcoming key milestones Biocryst Pharmaceuticals Inc today reported financial results for the fourth quarter and full year ended 31 December 2023, and provided a corporate update. Jon Stonehouse, President and Chief Executive Officer of BioCryst. “The impressive growth we are seeing with Orladeyo [...]